September 5, 2016
A de-facto restriction that was to be issued over the use of Taltz (ixekizumab), Eli Lilly’s new psoriasis drug, has shocked the pharmaceutical industry, with many questioning whether such decision was appropriate despite coming amid pressure to curtail drug spending...read more